Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for ... MarketWatch (press release) Moderate-to-severe plaque PsO in adults who failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapy including cyclosporine, methotrexate or PUVA (psoralen plus ultraviolet A light). ... RemicadeĀ® (Infliximab) Receives Positive Opinion From CHMP In Europe for ... |
